/SLS
SLS Stock - SELLAS Life Sciences Group, Inc.
Healthcare|BiotechnologyNASDAQ
$2.36+0.85%
+$0.02 (+0.85%) • Dec 19
68
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.93
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).87
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.19
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+18.6%upside
Target: $2.80
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SLS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.34 – $2.38
TARGET (TP)$2.80
STOP LOSS$2.17
RISK/REWARD1:2.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.52
52W High$2.48
52W Low$0.85
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $1.00M | $7.60M | $1.90M |
| Gross Profit | N/A | N/A | $900,000 | $7.40M | $1.90M |
| Gross Margin | N/A | N/A | 90.0% | 97.4% | 100.0% |
| Operating Income | $-31,513,000 | $-37,869,000 | $-41,950,000 | $-25,294,000 | $-16,982,000 |
| Net Income | $-30,881,000 | $-37,340,000 | $-41,301,000 | $-20,699,000 | $-16,757,000 |
| Net Margin | N/A | N/A | -4130.1% | -272.4% | -881.9% |
| EPS | $-0.05 | $-0.15 | $-2.13 | $-1.34 | $-2.11 |
Company Overview
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
SLSBeat Rate
50%
Last 18 quarters
Avg Surprise
-108.4%
EPS vs Estimate
Beats / Misses
9/9
Last 12 quarters
Latest EPS
$-0.06
Q4 2025
EPS Surprise History
Q1 24
-388.5%
$-0.25vs$0.09
Q2 24
-31.2%
$-0.21vs$-0.16
Q3 24
+18.8%
$-0.13vs$-0.16
Q4 24
+23.1%
$-0.10vs$-0.13
Q1 25
+27.3%
$-0.08vs$-0.11
Q2 25
+30.0%
$-0.07vs$-0.10
Q3 25
+16.0%
$-0.07vs$-0.08
Q4 25
+18.2%
$-0.06vs$-0.07
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 19, 2026 | — | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.07 | $-0.06 | +18.2% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.08 | $-0.07 | +16.0% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.10 | $-0.07 | +30.0% | ✓ BEAT |
Q1 2025 | Mar 20, 2025 | $-0.11 | $-0.08 | +27.3% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.13 | $-0.10 | +23.1% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-0.16 | $-0.13 | +18.8% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.16 | $-0.21 | -31.2% | ✗ MISS |
Q1 2024 | Mar 28, 2024 | $0.09 | $-0.25 | -388.5% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.03 | $-0.33 | -1200.2% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.35 | $-0.31 | +11.4% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.29 | $-0.47 | -62.1% | ✗ MISS |
Q1 2023 | Mar 16, 2023 | $0.32 | $-0.43 | -234.4% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.39 | $-0.34 | +12.8% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.35 | $-0.41 | -17.1% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.38 | $-1.05 | -176.3% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | $-0.40 | $-0.42 | -4.1% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | $-0.38 | $-0.45 | -18.4% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.39 | $-0.30 | +23.1% | ✓ BEAT |
Latest News
SELLAS Life Sciences Announced Sunday, SLS009 In Combination With AZA/VEN Achieved 46% Overall Response Rate Across All Cohorts, 58% Overall Response Rate In Patients With One Prior Line Of Therapy In AML-MR Study
📈 PositiveBenzinga•Dec 7, 2025, 11:25 PM
SELLAS Life Sciences Gr Q3 EPS $(0.06) Beats $(0.09) Estimate
📈 PositiveBenzinga•Nov 12, 2025, 09:52 PM
SELLAS Life Sciences To Present Data From Ongoing Phase 2 Study Of SLS009 For Treatment Of r/r AML At ASH 2025
➖ NeutralBenzinga•Nov 3, 2025, 02:12 PM
SELLAS Life Sciences Group Announces Exercise Of Warrants To Purchase Up To 22,363,714 Shares For Gross Cash Proceeds ~$31M
📈 PositiveBenzinga•Oct 27, 2025, 12:50 PM
SELLAS Life Sciences Gr Option Alert: Feb 20 $2.5 Calls Sweep (37) near the Ask: 6320 @ $0.601 vs 0 OI; Earnings 11/12 After Close [est] Ref=$2.
➖ NeutralBenzinga•Oct 14, 2025, 03:43 PM
SELLAS Life Sciences To Present Preclinical Efficacy Of Highly Selective CDK9 Inhibitor, SLS009, As Monotherapy And In Combination With Venetoclax In T-Cell Prolymphocytic Leukemia, At ESMO Congress 2025
📈 PositiveBenzinga•Oct 13, 2025, 12:09 PM
SELLAS Life Sciences Group Files For Offer And Resale By Selling Stockholders Up To 19,685,040 Shares Of Common Stock.
📉 NegativeBenzinga•Oct 10, 2025, 08:13 PM
SELLAS Life Sciences Group Announces Exercise Of Warrants Held By Institutional Investor To Purchase Up To 19,685,040 Shares For Gross Proceeds ~$23.6M
📈 PositiveBenzinga•Sep 11, 2025, 12:36 PM
SELLAS Life Sciences Gr Option Alert: Jan, 2027 $2.5 Calls Sweep (97) near the Ask: 1155 @ $0.451 vs 8362 OI; Ref=$1.785
📈 PositiveBenzinga•Aug 20, 2025, 02:02 PM
Frequently Asked Questions about SLS
What is SLS's current stock price?
SELLAS Life Sciences Group, Inc. (SLS) is currently trading at $2.36 per share. The stock has moved +0.85% today.
What is the analyst price target for SLS?
The average analyst price target for SLS is $2.80, based on 1 analyst.
What sector is SELLAS Life Sciences Group, Inc. in?
SELLAS Life Sciences Group, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SLS's market cap?
SELLAS Life Sciences Group, Inc. has a market capitalization of $0.25 billion, making it a small-cap company.
Does SLS pay dividends?
No, SELLAS Life Sciences Group, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARMP
Armata Pharmaceuticals, Inc.
$6.16
Mkt Cap: $0.2B
CCCC
C4 Therapeutics, Inc.
$2.03
Mkt Cap: $0.1B
CDXS
Codexis, Inc.
$1.66
Mkt Cap: $0.1B
GNFT
Genfit S.A.
$5.61
Mkt Cap: $0.3B
IVVD
Invivyd, Inc.
$2.30
Mkt Cap: $0.3B
MDWD
MediWound Ltd.
$18.77
Mkt Cap: $0.2B
NTHI
Neonc Technologies Holdings, Inc.
$7.01
Mkt Cap: $0.1B
OABI
OmniAb, Inc.
$2.09
Mkt Cap: $0.2B
PRLD
Prelude Therapeutics Incorporated
$2.14
Mkt Cap: $0.2B
TARA
Protara Therapeutics, Inc.
$5.27
Mkt Cap: $0.2B
Explore stocks similar to SLS for comparison